HemOnc Today Current Issue

The following articles appeared in the print edition of HemOnc Today.

Table of Contents

• Efforts to reduce racial disparities in cancer care aim to ‘make the invisible visible’
• Navigators support, empower minority patients with cancer
• Big data, big errors of interpretation Derek Raghavan, MD, PhD, FACP, FRACP, FASCO
• Understanding breast implant-associated anaplastic large cell lymphoma Sameer A. Patel, MD, FACS
• APP-driven oncology urgent care can improve patient satisfaction, quality of life Vanna M. Dest, MSN, APRN-BC, AOCN
• Periventricular germinoma with leptomeningeal dissemination: A case report Munir Ghesani, MD, FACNM; David Zagzag, MD; Ana M. Franceschi, MD; Jonathan Howard, MD; Benjamin T. Cooper, MD; Nikhil A. Sahasrabudhe, MD
• ‘We have to cure’ cancer, says CAR T pioneer Carl H. June, MD
• ASCO president-elect wants ‘new and different viewpoints at the table’
• Corticosteroid use for immune-mediated adverse events often does not match guidelines
• Fungal infections uncommon among ibrutinib-treated patients despite low rate of prophylaxis
• Rapidly expanding treatment options improving survival in acute myeloid leukemia
• Cost of cancer care under scrutiny, projected to keep rising
• Surgery prolongs survival in HER2-positive advanced breast cancer
• Immunotherapy combination of nivolumab, ipilimumab confers benefit in rare neuroendocrine carcinoma
• Immunotherapy, chemotherapy combination shows promising antitumor activity in metastatic pancreatic cancer
• Gilteritinib represents ‘major change’ for treatment of relapsed, refractory acute myeloid leukemia
• Next-generation TRK inhibitor demonstrates efficacy in tumors with emergent resistance mutations
• Adults at high risk for HIV show ‘alarmingly’ low HPV vaccination rate
• Tools to better assess tumor heterogeneity will ‘shed new light’ on cancer research, treatment
• HER2-targeted CAR T cells safely induce responses in advanced HER2-positive sarcoma
• CAR T-cell therapy shows promise for mesothelin-expressing solid tumors
• Pembrolizumab shows durable benefit as third-line treatment of advanced small cell lung cancer
• Experts debate partial breast irradiation vs. omission of radiation therapy for low-risk breast cancer
• Work ‘not yet done’ in management of HER2-positive breast cancer
• Darolutamide reduces risk for metastases in prostate cancer
• Pembrolizumab plus olaparib safe, active in docetaxel-pretreated men with prostate cancer
• First-line avelumab, axitinib benefit persists across advanced kidney cancer patient subgroups
• Retroperitoneal lymph node dissection demonstrates ‘excellent’ survival rates for testicular seminoma
• Lentiviral gene therapy with busulfan conditioning safe, effective in infants with SCID-X1
• Opioid-related hospitalizations uncommon, but slowly rising, among patients with cancer
• Complementary medicine use common, often undisclosed by patients with, survivors of cancer
• Recent FDA approvals in oncology
• FDA places partial clinical hold on venetoclax trials for multiple myeloma
• FDA clears liquid biopsy test to monitor response to chronic myeloid leukemia treatment
• FDA weighs breast implant risks, benefits amid links to cancer, other illnesses